Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A prospective study of bisphosphonate use and risk of colorectal cancer.

Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT.

J Clin Oncol. 2012 Sep 10;30(26):3229-33. doi: 10.1200/JCO.2011.39.2670. Epub 2012 May 29.

2.

Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative.

Passarelli MN, Newcomb PA, LaCroix AZ, Lane DS, Ho GY, Chlebowski RT.

J Bone Miner Res. 2013 Sep;28(9):2043-8. doi: 10.1002/jbmr.1930.

3.

Exposure to oral bisphosphonates and risk of esophageal cancer.

Cardwell CR, Abnet CC, Cantwell MM, Murray LJ.

JAMA. 2010 Aug 11;304(6):657-63. doi: 10.1001/jama.2010.1098.

4.

Associations of self-reported sleep duration and snoring with colorectal cancer risk in men and women.

Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S, Willett WC, Ma J.

Sleep. 2013 May 1;36(5):681-8. doi: 10.5665/sleep.2626.

5.

Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.

Oh YH, Yoon C, Park SM.

World J Gastroenterol. 2012 Oct 28;18(40):5779-88. doi: 10.3748/wjg.v18.i40.5779. Review.

6.

Exposure to oral bisphosphonates and risk of cancer.

Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ.

Int J Cancer. 2012 Sep 1;131(5):E717-25. doi: 10.1002/ijc.27389. Epub 2012 Jan 11.

7.

Coffee consumption and the risk of colorectal cancer: a prospective cohort study in Japan.

Naganuma T, Kuriyama S, Akhter M, Kakizaki M, Nakaya N, Matsuda-Ohmori K, Shimazu T, Fukao A, Tsuji I.

Int J Cancer. 2007 Apr 1;120(7):1542-7.

8.

Reproductive history and risk of colorectal cancer in postmenopausal women.

Zervoudakis A, Strickler HD, Park Y, Xue X, Hollenbeck A, Schatzkin A, Gunter MJ.

J Natl Cancer Inst. 2011 May 18;103(10):826-34. doi: 10.1093/jnci/djr101. Epub 2011 Mar 29.

9.

Oral bisphosphonate use and breast cancer incidence in postmenopausal women.

Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB.

J Clin Oncol. 2010 Aug 1;28(22):3582-90. doi: 10.1200/JCO.2010.28.2095. Epub 2010 Jun 21.

10.

Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.

Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS.

Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):810-7. doi: 10.1002/pds.3292. Epub 2012 Jun 19.

PMID:
22711458
11.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
12.

Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk.

Simon MS, Rosenberg CA, Rodabough RJ, Greenland P, Ockene I, Roy HK, Lane DS, Cauley JA, Khandekar J.

Ann Epidemiol. 2012 Jan;22(1):17-27. doi: 10.1016/j.annepidem.2011.10.006. Epub 2011 Nov 4.

13.

Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study.

Kremer R, Gagnon B, Meguerditchian AN, Nadeau L, Mayo N.

J Natl Cancer Inst. 2014 Oct 2;106(11). pii: dju264. doi: 10.1093/jnci/dju264. Print 2014 Nov.

PMID:
25278509
14.

Prospective cohort studies of bowel movement frequency and laxative use and colorectal cancer incidence in US women and men.

Zhang X, Wu K, Cho E, Ma J, Chan AT, Gao X, Willett WC, Fuchs CS, Giovannucci EL.

Cancer Causes Control. 2013 May;24(5):1015-24. doi: 10.1007/s10552-013-0176-2. Epub 2013 Mar 2.

15.

Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort.

Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ.

Am J Gastroenterol. 2011 Jul;106(7):1340-50. doi: 10.1038/ajg.2011.38. Epub 2011 Mar 15.

16.

Oral bisphosphonate use and risk of postmenopausal endometrial cancer.

Newcomb PA, Passarelli MN, Phipps AI, Anderson GL, Wactawski-Wende J, Ho GY, O'Sullivan MJ, Chlebowski RT.

J Clin Oncol. 2015 Apr 1;33(10):1186-90. doi: 10.1200/JCO.2014.58.6842. Epub 2015 Feb 23.

17.

Italian Mediterranean Index and risk of colorectal cancer in the Italian section of the EPIC cohort.

Agnoli C, Grioni S, Sieri S, Palli D, Masala G, Sacerdote C, Vineis P, Tumino R, Giurdanella MC, Pala V, Berrino F, Mattiello A, Panico S, Krogh V.

Int J Cancer. 2013 Mar 15;132(6):1404-11. doi: 10.1002/ijc.27740. Epub 2012 Aug 7.

18.

Oral bisphosphonates and the risk of colorectal cancer: a meta-analysis.

Yang G, Hu H, Zeng R, Huang J.

J Clin Gastroenterol. 2013 Oct;47(9):741-8. doi: 10.1097/MCG.0b013e31829e446b.

PMID:
24030705
19.

Bisphosphonates for breast cancer.

Pavlakis N, Stockler M.

Cochrane Database Syst Rev. 2002;(1):CD003474. Review. Update in: Cochrane Database Syst Rev. 2005;(3):CD003474.

PMID:
11869664
20.

Bisphosphonate use and risk of colorectal cancer: a systematic review and meta-analysis.

Bonovas S, Nikolopoulos G, Bagos P.

Br J Clin Pharmacol. 2013 Sep;76(3):329-37. doi: 10.1111/bcp.12135.

Supplemental Content

Support Center